CN111448313A - 用于改善基于Cas9的敲入策略的有效性的组合物和方法 - Google Patents

用于改善基于Cas9的敲入策略的有效性的组合物和方法 Download PDF

Info

Publication number
CN111448313A
CN111448313A CN201880073647.3A CN201880073647A CN111448313A CN 111448313 A CN111448313 A CN 111448313A CN 201880073647 A CN201880073647 A CN 201880073647A CN 111448313 A CN111448313 A CN 111448313A
Authority
CN
China
Prior art keywords
sequence
endonuclease
cas
cas9
polynucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880073647.3A
Other languages
English (en)
Chinese (zh)
Inventor
M.马尔斯卡
A.塔赫里-加赫法罗基
F.卡尔松
M.博卢利-耶加内
L.M.迈尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Priority to CN202510144781.XA priority Critical patent/CN120310773A/zh
Publication of CN111448313A publication Critical patent/CN111448313A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
    • C12Y301/21004—Type II site-specific deoxyribonuclease (3.1.21.4)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/24—Vectors characterised by the absence of particular element, e.g. selectable marker, viral origin of replication
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00—Vectors comprising a targeting moiety
    • C12N2810/40—Vectors comprising a peptide as targeting moiety, e.g. a synthetic peptide, from undefined source
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2521/00—Reaction characterised by the enzymatic activity
    • C12Q2521/30—Phosphoric diester hydrolysing, i.e. nuclease
    • C12Q2521/301—Endonuclease

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201880073647.3A 2017-11-16 2018-11-16 用于改善基于Cas9的敲入策略的有效性的组合物和方法 Pending CN111448313A (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202510144781.XA CN120310773A (zh) 2017-11-16 2018-11-16 用于改善基于Cas9的敲入策略的有效性的组合物和方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762587029P 2017-11-16 2017-11-16
US62/587029 2017-11-16
US201862693690P 2018-07-03 2018-07-03
US62/693690 2018-07-03
PCT/US2018/061680 WO2019099943A1 (en) 2017-11-16 2018-11-16 Compositions and methods for improving the efficacy of cas9-based knock-in strategies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202510144781.XA Division CN120310773A (zh) 2017-11-16 2018-11-16 用于改善基于Cas9的敲入策略的有效性的组合物和方法

Publications (1)

Publication Number Publication Date
CN111448313A true CN111448313A (zh) 2020-07-24

Family

ID=64870555

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201880073647.3A Pending CN111448313A (zh) 2017-11-16 2018-11-16 用于改善基于Cas9的敲入策略的有效性的组合物和方法
CN202510144781.XA Pending CN120310773A (zh) 2017-11-16 2018-11-16 用于改善基于Cas9的敲入策略的有效性的组合物和方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202510144781.XA Pending CN120310773A (zh) 2017-11-16 2018-11-16 用于改善基于Cas9的敲入策略的有效性的组合物和方法

Country Status (5)

Country Link
US (2) US20210180059A1 (https=)
EP (1) EP3710583A1 (https=)
JP (3) JP7423520B2 (https=)
CN (2) CN111448313A (https=)
WO (1) WO2019099943A1 (https=)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113481184A (zh) * 2021-08-06 2021-10-08 北京大学 融合蛋白以及其使用方法
CN114410625A (zh) * 2012-03-20 2022-04-29 维尔纽斯大学 通过Cas9-crRNA复合物的RNA指导的DNA裂解
CN114438235A (zh) * 2020-11-04 2022-05-06 深圳市南山区疾病预防控制中心 一种同时检测嗜低温弓形杆菌及斯氏弓形杆菌的引物探针组件、试剂盒及其应用
CN119614679A (zh) * 2023-09-14 2025-03-14 厦门大学 一款通用型核酸检测平台

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3204496A1 (en) 2014-10-10 2017-08-16 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
WO2018119010A1 (en) 2016-12-19 2018-06-28 Editas Medicine, Inc. Assessing nuclease cleavage
EP3565907B1 (en) 2017-01-06 2022-05-04 Editas Medicine, Inc. Methods of assessing nuclease cleavage
US11499151B2 (en) 2017-04-28 2022-11-15 Editas Medicine, Inc. Methods and systems for analyzing guide RNA molecules
WO2018227114A1 (en) 2017-06-09 2018-12-13 Editas Medicine, Inc. Engineered cas9 nucleases
US11866726B2 (en) 2017-07-14 2024-01-09 Editas Medicine, Inc. Systems and methods for targeted integration and genome editing and detection thereof using integrated priming sites
AU2018316166A1 (en) 2017-08-07 2020-02-06 The Regents Of The University Of California Platform for generating safe cell therapeutics
KR20210045360A (ko) 2018-05-16 2021-04-26 신테고 코포레이션 가이드 rna 설계 및 사용을 위한 방법 및 시스템
EP3823633A4 (en) 2018-06-29 2023-05-03 Editas Medicine, Inc. SYNTHETIC LEAD MOLECULES, COMPOSITIONS AND METHODS RELATED THERETO
US11530425B2 (en) 2019-10-09 2022-12-20 Massachusetts Institute Of Technology Systems, methods, and compositions for correction of frameshift mutations
CN115427566A (zh) * 2020-04-08 2022-12-02 阿斯利康(瑞典)有限公司 用于改善的位点特异性修饰的组合物和方法
JP2023540427A (ja) * 2020-07-07 2023-09-25 オリエンジーン バイオテクノロジー リミテッド Ｈｓｖ－１遺伝子編集のためのガイドｒｎａおよびその方法
JP2024513087A (ja) * 2021-04-07 2024-03-21 アストラゼネカ・アクチエボラーグ 部位特異的改変のための組成物及び方法
CN117396602A (zh) 2021-05-27 2024-01-12 阿斯利康(瑞典)有限公司 具有增强的稳定性的cas9效应蛋白
WO2023052508A2 (en) 2021-09-30 2023-04-06 Astrazeneca Ab Use of inhibitors to increase efficiency of crispr/cas insertions
CN118715317A (zh) * 2021-12-15 2024-09-27 武汉大学 Dna聚合酶介导的基因组编辑
CN121127605A (zh) 2023-03-29 2025-12-12 阿斯利康(瑞典)有限公司 使用抑制剂来提高CRISPR/Cas插入的效率
CN116949012B (zh) * 2023-09-20 2024-01-02 广州瑞风生物科技有限公司 一种融合蛋白及其应用
EP4678742A1 (en) 2024-07-10 2026-01-14 Astrazeneca AB Improved cas9 proteins

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160032321A1 (en) * 2012-08-28 2016-02-04 Novartis Ag Methods of nuclease-based genetic engineering
WO2016205711A1 (en) * 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
WO2017010543A1 (ja) * 2015-07-14 2017-01-19 国立大学法人東京大学 改変されたＦｎＣａｓ９タンパク質及びその使用
US20170306335A1 (en) * 2014-12-23 2017-10-26 The Broad Institute Inc. Rna-targeting system
WO2017189308A1 (en) * 2016-04-19 2017-11-02 The Broad Institute Inc. Novel crispr enzymes and systems
WO2017189336A1 (en) * 2016-04-25 2017-11-02 The Regents Of The University Of California Methods and compositions for genomic editing

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5895309A (en) 1998-02-09 1999-04-20 Spector; Donald Collapsible hula-hoop
JP2008078613A (ja) 2006-08-24 2008-04-03 Rohm Co Ltd 窒化物半導体の製造方法及び窒化物半導体素子
ES2646630T3 (es) 2008-11-07 2017-12-14 Massachusetts Institute Of Technology Lipidoides aminoalcohólicos y usos de los mismos
US8889394B2 (en) 2009-09-07 2014-11-18 Empire Technology Development Llc Multiple domain proteins
EP2609135A4 (en) 2010-08-26 2015-05-20 Massachusetts Inst Technology POLY (BETA AMINO ALCOHOLS), THEIR PREPARATION AND USES THEREOF
US9238716B2 (en) 2011-03-28 2016-01-19 Massachusetts Institute Of Technology Conjugated lipomers and uses thereof
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
EP3241902B1 (en) 2012-05-25 2018-02-28 The Regents of The University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
KR102530118B1 (ko) 2012-07-25 2023-05-08 더 브로드 인스티튜트, 인코퍼레이티드 유도 ｄｎａ 결합 단백질 및 게놈 교란 도구 및 이의 적용
EP3363902B1 (en) 2012-12-06 2019-11-27 Sigma Aldrich Co. LLC Crispr-based genome modification and regulation
CA2894684A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Engineering and optimization of improved crispr-cas systems, methods and enzyme compositions for sequence manipulation in eukaryotes
CN105121648B (zh) * 2012-12-12 2021-05-07 布罗德研究所有限公司 用于序列操纵的系统、方法和优化的指导组合物的工程化
DK2931897T3 (en) 2012-12-12 2018-02-05 Broad Inst Inc CONSTRUCTION, MODIFICATION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION AND THERAPEUTICAL APPLICATIONS
WO2014118272A1 (en) 2013-01-30 2014-08-07 Santaris Pharma A/S Antimir-122 oligonucleotide carbohydrate conjugates
US9234213B2 (en) 2013-03-15 2016-01-12 System Biosciences, Llc Compositions and methods directed to CRISPR/Cas genomic engineering systems
AU2014227653B2 (en) 2013-03-15 2017-04-20 The General Hospital Corporation Using RNA-guided foki nucleases (RFNs) to increase specificity for RNA-guided genome editing
EP3778899A1 (en) 2013-05-22 2021-02-17 Northwestern University Rna-directed dna cleavage and gene editing by cas9 enzyme from neisseria meningitidis
EP3011030B1 (en) 2013-06-17 2023-11-08 The Broad Institute, Inc. Optimized crispr-cas double nickase systems, methods and compositions for sequence manipulation
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
JP6793547B2 (ja) 2013-12-12 2020-12-02 ザ・ブロード・インスティテュート・インコーポレイテッド 最適化機能ＣＲＩＳＰＲ−Ｃａｓ系による配列操作のための系、方法および組成物
WO2015089364A1 (en) * 2013-12-12 2015-06-18 The Broad Institute Inc. Crystal structure of a crispr-cas system, and uses thereof
EP3470089A1 (en) * 2013-12-12 2019-04-17 The Broad Institute Inc. Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components
BR112016013207A2 (pt) * 2013-12-12 2017-09-26 Massachusetts Inst Technology administração, uso e aplicações terapêuticas dos sistemas crispr-cas e composições para o hbv e distúrbios e doenças virais
ES2730378T3 (es) * 2014-08-27 2019-11-11 Caribou Biosciences Inc Procedimientos para incrementar la eficiencia de la modificación mediada por Cas9
US10858662B2 (en) 2014-11-19 2020-12-08 Institute For Basic Science Genome editing with split Cas9 expressed from two vectors
EP3250691B9 (en) 2015-01-28 2023-08-02 Caribou Biosciences, Inc. Crispr hybrid dna/rna polynucleotides and methods of use
EP3303634B1 (en) * 2015-06-03 2023-08-30 The Regents of The University of California Cas9 variants and methods of use thereof
WO2016205759A1 (en) * 2015-06-18 2016-12-22 The Broad Institute Inc. Engineering and optimization of systems, methods, enzymes and guide scaffolds of cas9 orthologs and variants for sequence manipulation
US11479793B2 (en) * 2015-07-15 2022-10-25 Rutgers, The State University Of New Jersey Nuclease-independent targeted gene editing platform and uses thereof
WO2017151444A1 (en) * 2016-02-29 2017-09-08 Agilent Technologies, Inc. Methods and compositions for blocking off-target nucleic acids from cleavage by crispr proteins
EP3699281A1 (en) * 2016-03-11 2020-08-26 Pioneer Hi-Bred International, Inc. Novel cas9 systems and methods of use
CA3010628A1 (en) * 2016-03-11 2017-09-14 Pioneer Hi-Bred International, Inc. Novel cas9 systems and methods of use
CN116850305A (zh) * 2016-05-06 2023-10-10 朱诺治疗学股份有限公司 基因工程化细胞及其制备方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20160032321A1 (en) * 2012-08-28 2016-02-04 Novartis Ag Methods of nuclease-based genetic engineering
US20170306335A1 (en) * 2014-12-23 2017-10-26 The Broad Institute Inc. Rna-targeting system
WO2016205711A1 (en) * 2015-06-18 2016-12-22 The Broad Institute Inc. Novel crispr enzymes and systems
WO2017010543A1 (ja) * 2015-07-14 2017-01-19 国立大学法人東京大学 改変されたＦｎＣａｓ９タンパク質及びその使用
WO2017189308A1 (en) * 2016-04-19 2017-11-02 The Broad Institute Inc. Novel crispr enzymes and systems
WO2017189336A1 (en) * 2016-04-25 2017-11-02 The Regents Of The University Of California Methods and compositions for genomic editing

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ACCESSION：WP_003042179.1: "type II-B CRISPR-associated RNA-guided endonuclease Cas9/Csx12 [Francisella tularensis]", 《NCBI》, 7 October 2015 (2015-10-07) *
ACCESSION：WP_096025442.1: "hypothetical protein [Campylobacter lanienae]", 《NCBI》, 19 September 2017 (2017-09-19) *
ANDREW R. BASSETT等: "Highly Efficient Targeted Mutagenesis of Drosophila with the CRISPR/Cas9 System", 《CELL REPORTS》, vol. 4, no. 1, 1 July 2013 (2013-07-01), pages 220 - 228 *
ANDREW R. BASSETT等: "Highly Efficient Targeted Mutagenesis of Drosophila with the CRISPR/Cas9 System", 《CELL REPORTS》, vol. 4, no. 1, pages 220 - 228 *
JOHN P GUILINGER等: "Fusion of catalytically inactive Cas9 to FokI nuclease improves the specificity of genome modification", 《NATURE BIOTECHNOLOGY》, vol. 32, pages 577 - 582, XP055157221, DOI: 10.1038/nbt.2909 *
ZHICHENG ZUO等: "Cas9-catalyzed DNA Cleavage Generates Staggered Ends: Evidence from Molecular Dynamics Simulations", 《SCITIFIC REPORTS》, vol. 5, 22 November 2016 (2016-11-22), pages 37584 *
ZHICHENG ZUO等: "Cas9-catalyzed DNA Cleavage Generates Staggered Ends: Evidence from Molecular Dynamics Simulations", 《SCITIFIC REPORTS》, vol. 5, pages 37584 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114410625A (zh) * 2012-03-20 2022-04-29 维尔纽斯大学 通过Cas9-crRNA复合物的RNA指导的DNA裂解
CN114410625B (zh) * 2012-03-20 2024-06-25 维尔纽斯大学 通过Cas9-crRNA复合物的RNA指导的DNA裂解
CN114438235A (zh) * 2020-11-04 2022-05-06 深圳市南山区疾病预防控制中心 一种同时检测嗜低温弓形杆菌及斯氏弓形杆菌的引物探针组件、试剂盒及其应用
CN113481184A (zh) * 2021-08-06 2021-10-08 北京大学 融合蛋白以及其使用方法
WO2023011638A1 (zh) * 2021-08-06 2023-02-09 北京大学 融合蛋白以及其使用方法
CN119614679A (zh) * 2023-09-14 2025-03-14 厦门大学 一款通用型核酸检测平台
WO2025055382A1 (zh) * 2023-09-14 2025-03-20 厦门大学 一款通用型核酸检测平台

Also Published As

Publication number Publication date
CN120310773A (zh) 2025-07-15
JP7423520B2 (ja) 2024-01-29
JP2025121906A (ja) 2025-08-20
JP2024050637A (ja) 2024-04-10
US20210180059A1 (en) 2021-06-17
US20250034562A1 (en) 2025-01-30
WO2019099943A1 (en) 2019-05-23
EP3710583A1 (en) 2020-09-23
JP7703707B2 (ja) 2025-07-07
JP2021503279A (ja) 2021-02-12

Similar Documents

Publication Publication Date Title
JP7703707B2 (ja) Ｃａｓ９ベースノックイン方針の効力を改善するための組成物及び方法
JP6737974B1 (ja) ヌクレアーゼ媒介ｄｎａアセンブリ
US10913941B2 (en) Enzymes with RuvC domains
KR102687373B1 (ko) 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
JP7201153B2 (ja) プログラム可能ｃａｓ９－リコンビナーゼ融合タンパク質およびその使用
JP2022043042A (ja) 遺伝子編集用のｃａｓ多様体
CN115427566A (zh) 用于改善的位点特异性修饰的组合物和方法
CN106795521A (zh) 用于修饰所靶向基因座的方法和组合物
KR20210042130A (ko) Acidaminococcus sp. cpf1의 dna 절단 활성을 향상시키는 신규한 돌연변이
EP4159853A1 (en) Genome editing system and method
AU2017302657A1 (en) Mice comprising mutations resulting in expression of c-truncated fibrillin-1
US20220220460A1 (en) Enzymes with ruvc domains
JP2024501892A (ja) 新規の核酸誘導型ヌクレアーゼ
US20250122535A1 (en) Crispr-associated transposases and methods of use thereof
CN113795588B (zh) 用于在靶向性载体中无瘢痕引入靶向修饰的方法
US20210163940A1 (en) Compositions and methods for nicking target dna sequences
JP2003116551A (ja) １つの遺伝系における組換え酵素による多重連続組換えのための、認識配列変異体の使用
CN116867897A (zh) 碱基编辑酶

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20200724